EyePoint Pharmaceuticals, Inc. (EYPT) financial statements (2022 and earlier)

Company profile

Business Address 480 PLEASANT STREET
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
6/30/2018
6/30/2017
6/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:211,600 22,21438,77616,89828,992
Cash and cash equivalents178,593 22,21438,77616,89815,313
Short-term investments65,965    13,679
Other undisclosed cash, cash equivalents, and short-term investments(32,958)     
Receivables414     
Inventory, net of allowances, customer advances and progress billings3,616 2,138   
Inventory3,616 2,138   
Other undisclosed current assets22,115 17,3651,133842971
Total current assets:237,745 41,71739,90917,74029,963
Noncurrent Assets
Operating lease, right-of-use asset2,252 3,078
Property, plant and equipment476 357253313290
Intangible assets, net (including goodwill)22,749 27,66931,3583641,102
Intangible assets, net (excluding goodwill)22,749 27,66931,3583641,102
Restricted cash and investments150 150150150150
Other undisclosed noncurrent assets    110114
Total noncurrent assets:25,627 31,25431,7619371,656
TOTAL ASSETS:263,372 72,97171,67018,67731,619
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities21,807 11,0246,6635,2404,946
Accounts payable7,385 4,1922,9401,0161,363
Accrued liabilities14,422 6,8323,7234,2243,583
Deferred revenue1,069 15
Debt  481   
Deferred revenue and credits 50147
Other liabilities782     
Other undisclosed current liabilities   15,000  
Total current liabilities:23,658 11,52021,6635,2905,093
Noncurrent Liabilities
Long-term debt and lease obligation38,422 50,12117,309  
Long-term debt, excluding current maturities36,562 47,22317,309  
Operating lease, liability1,860 2,898
Liabilities, other than long-term debt16,912 3,00021,011515,645
Deferred revenue and credits 515,645
Deferred revenue14,560  
Other liabilities2,352 3,0001,231  
Derivative instruments and hedges, liabilities   19,780  
Total noncurrent liabilities:55,334 53,12138,320515,645
Total liabilities:78,992 64,64159,9835,34110,738
Stockholders' equity
Stockholders' equity attributable to parent184,380 8,33011,68713,33620,881
Common stock34 109743934
Additional paid in capital752,602 472,667374,766323,284312,208
Accumulated other comprehensive income841 840838833852
Accumulated deficit(569,097) (465,286)(363,991)(310,820)(292,213)
Total stockholders' equity:184,380 8,33011,68713,33620,881
TOTAL LIABILITIES AND EQUITY:263,372 72,97171,67018,67731,619

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
6/30/2018
6/30/2017
6/30/2016
Revenues36,939 20,3652,9617,5391,620
Revenue, net 7,5391,620
Cost of revenue
(Cost of Goods and Services Sold)
(1,278)     
Gross profit:35,661 20,3652,9617,5391,620
Operating expenses(92,215) (68,226)(29,235)(26,115)(23,394)
Other undisclosed operating income1,278     
Operating loss:(55,276) (47,861)(26,274)(18,576)(21,774)
Nonoperating income (expense)(3,141) (8,932)(26,177)9172
Investment income, nonoperating   (26,278)  
Other nonoperating income292 1,0541019172
Interest and debt expense2,065 (3,810)(720)  
Loss from continuing operations before equity method investments, income taxes:(56,352) (60,603)(53,171)(18,485)(21,702)
Other undisclosed income (loss) from continuing operations before income taxes(2,065) 3,810   
Loss from continuing operations before income taxes:(58,417) (56,793)(53,171)(18,485)(21,702)
Income tax benefit     155
Net loss available to common stockholders, diluted:(58,417) (56,793)(53,171)(18,485)(21,547)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
6/30/2018
6/30/2017
6/30/2016
Net loss:(58,417) (56,793)(53,171)(18,485)(21,547)
Other comprehensive income (loss)  15(19)(93)
Comprehensive loss, net of tax, attributable to parent:(58,417) (56,792)(53,166)(18,504)(21,640)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: